MCID: MNC006
MIFTS: 51

Monoclonal Gammopathy of Uncertain Significance

Categories: Rare diseases, Cancer diseases, Immune diseases, Blood diseases

Aliases & Classifications for Monoclonal Gammopathy of Uncertain Significance

MalaCards integrated aliases for Monoclonal Gammopathy of Uncertain Significance:

Name: Monoclonal Gammopathy of Uncertain Significance 12 15
Monoclonal Gammopathy of Undetermined Significance 12 76 53 73
Mgus 12 53

Classifications:



External Ids:

Disease Ontology 12 DOID:7442
ICD10 33 D47.2
UMLS 73 C0026470

Summaries for Monoclonal Gammopathy of Uncertain Significance

NIH Rare Diseases : 53 Monoclonal gammopathy of undetermined significance (MGUS) is a condition in which an abnormal protein called monoclonal protein is detected in the blood. MGUS typically does not cause any problems, although some affected people may experience numbness, tingling or weakness. In some cases, MGUS may progress over time to certain forms of blood cancer (such as multiple myeloma, macroglobulinemia, or B-cell lymphoma). MGUS is thought to be a multifactorial condition that is likely associated with the effects of multiple genes in combination with lifestyle and environmental factors. People with MGUS are usually monitored closely to ensure that the levels of monoclonal protein do not rise and other problems do not develop. Those with stable levels of monoclonal protein typically do not require treatment.

MalaCards based summary : Monoclonal Gammopathy of Uncertain Significance, also known as monoclonal gammopathy of undetermined significance, is related to purpura and myeloma, multiple. An important gene associated with Monoclonal Gammopathy of Uncertain Significance is IL6 (Interleukin 6), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Allograft rejection. The drugs Liraglutide and Hormone Antagonists have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and b cells, and related phenotypes are cellular and cardiovascular system

Wikipedia : 76 Monoclonal gammopathy of undetermined significance (MGUS, unknown or uncertain may be substituted for... more...

Related Diseases for Monoclonal Gammopathy of Uncertain Significance

Diseases related to Monoclonal Gammopathy of Uncertain Significance via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 237)
# Related Disease Score Top Affiliating Genes
1 purpura 30.6 CD40LG CD79A TNF
2 myeloma, multiple 24.3 B2M CD19 CD38 CD40LG CD79A IL6
3 scorpion envenomation 11.0 IL6 TNF
4 leukomalacia 10.9 IL6 TNF
5 angioimmunoblastic lymphadenopathy with dysproteinemia 10.9 IL6 TNF
6 critical limb ischemia 10.9 IL6 TNF
7 retinitis pigmentosa 55 10.8 IL6 TNF
8 trench fever 10.8 CD40LG TNF
9 selective igg deficiency disease 10.8 CD40LG CD79A
10 c1q nephropathy 10.8 CD40LG CD79A
11 anca-associated vasculitis 10.8 IL6 TNF
12 rheumatoid lung disease 10.8 CD40LG TNF
13 meningovascular neurosyphilis 10.8 CD40LG CD79A
14 alpha chain disease 10.8 CD40LG CD79A
15 brill-zinsser disease 10.8 CD40LG CD79A
16 exudative glomerulonephritis 10.8 CD40LG CD79A
17 cork-handlers' disease 10.8 CD40LG CD79A
18 laryngitis 10.8 IL6 TNF
19 salpingo-oophoritis 10.8 CD40LG CD79A
20 early yaws 10.8 CD40LG CD79A
21 ventilation pneumonitis 10.8 CD40LG CD79A
22 chronic interstitial cystitis 10.8 CD40LG CD79A
23 axillary adenitis 10.8 CD40LG CD79A
24 cryofibrinogenemia 10.8 CD40LG CD79A
25 trichostrongyloidiasis 10.8 CD40LG CD79A
26 subacute bacterial endocarditis 10.7 CD40LG CD79A
27 heterophyiasis 10.7 CD40LG CD79A
28 immunoglobulin g deficiency 10.7 CD40LG CD79A
29 orbital granuloma 10.7 CD40LG CD79A
30 hyperglobulinemic purpura 10.7 CD40LG CD79A
31 gastroduodenitis 10.7 CD40LG CD79A
32 bacterial conjunctivitis 10.7 CD40LG CD79A
33 heavy chain disease 10.7 CD40LG CD79A
34 farmer's lung 10.7 CD79A TNF
35 indolent myeloma 10.7 B2M MYOM2
36 ophthalmia neonatorum 10.7 CD40LG CD79A
37 parotid disease 10.7 CD40LG CD79A
38 idiopathic achalasia 10.7 LTA TNF
39 cerebral arteritis 10.7 CD40LG CD79A
40 selective immunoglobulin deficiency disease 10.7 CD40LG CD79A
41 geniculate herpes zoster 10.7 CD40LG CD79A
42 smoldering myeloma 10.7 CD79A MYOM2
43 autoimmune disease of central nervous system 10.7 CD40LG MAG
44 erythema elevatum diutinum 10.7 CD40LG CD79A
45 sporotrichosis 10.7 CD40LG CD79A
46 fallopian tube disease 10.7 CD40LG CD79A
47 mononeuritis multiplex 10.7 CD40LG MAG
48 null-cell leukemia 10.7 IL6 LTA TNF
49 hyperimmunoglobulin syndrome 10.7 CD40LG CD79A
50 congenital syphilis 10.7 CD40LG CD79A

Graphical network of the top 20 diseases related to Monoclonal Gammopathy of Uncertain Significance:



Diseases related to Monoclonal Gammopathy of Uncertain Significance

Symptoms & Phenotypes for Monoclonal Gammopathy of Uncertain Significance

MGI Mouse Phenotypes related to Monoclonal Gammopathy of Uncertain Significance:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.06 CD38 MAFB CD40LG CD79A B2M IL6
2 cardiovascular system MP:0005385 10.03 LTA MAFB CD40LG B2M IL6 CD19
3 hematopoietic system MP:0005397 9.97 CD38 CD40LG CD79A B2M IL6 CD19
4 homeostasis/metabolism MP:0005376 9.96 CD38 MAFB CD40LG CD79A B2M IL6
5 endocrine/exocrine gland MP:0005379 9.91 LTA CD38 MAFB CD40LG B2M IL6
6 immune system MP:0005387 9.85 MAFB CD40LG MAG CD79A B2M IL6
7 liver/biliary system MP:0005370 9.43 LTA CD79A B2M IL6 CD19 TNF
8 nervous system MP:0003631 9.32 MAFB CD40LG MAG CD79A B2M IL6

Drugs & Therapeutics for Monoclonal Gammopathy of Uncertain Significance

Drugs for Monoclonal Gammopathy of Uncertain Significance (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 232)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Liraglutide Approved Phase 4 204656-20-2 44147092
2 Hormone Antagonists Phase 4,Phase 2,Phase 1
3 Hormones Phase 4,Phase 3,Phase 2,Phase 1
4 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 1
5 Antibodies Phase 4,Phase 2,Phase 1
6 Immunoglobulins Phase 4,Phase 2,Phase 1
7 glucagon Phase 4
8 Glucagon-Like Peptide 1 Phase 4
9 Hypoglycemic Agents Phase 4
10 Incretins Phase 4
11
rituximab Approved Phase 3,Phase 2 174722-31-7 10201696
12
Heparin Approved, Investigational Phase 3,Not Applicable 9005-49-6 772 46507594
13
Iron Approved Phase 3 7439-89-6 23925
14
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
15
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 1,Phase 2 22916-47-8 4189
16
Morphine Approved, Investigational Phase 3,Not Applicable 57-27-2 5288826
17
Ondansetron Approved Phase 3 99614-02-5 4595
18
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
19
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
20
Dalteparin Approved Phase 3 9005-49-6
21
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 11096-26-7, 209810-58-2
22
Caspofungin Approved Phase 3,Phase 2 179463-17-3, 162808-62-0 468682 2826718
23
Guaifenesin Approved, Investigational, Vet_approved Phase 3,Not Applicable 93-14-1 3516
24
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
25
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
26 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
27 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
28 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1,Not Applicable
29 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
30 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
31 Antiemetics Phase 3,Phase 2,Phase 1
32 Antirheumatic Agents Phase 3,Phase 2,Phase 1
33 Autonomic Agents Phase 3,Phase 2,Phase 1
34 ferric gluconate Phase 3
35 calcium heparin Phase 3,Not Applicable
36 Epoetin alfa Phase 3,Phase 2 113427-24-0
37 Analgesics Phase 3,Phase 2,Not Applicable
38 Ferric Compounds Phase 3
39 Fibrinolytic Agents Phase 3
40 Respiratory System Agents Phase 3,Not Applicable
41 Central Nervous System Depressants Phase 3,Not Applicable
42 Adjuvants, Anesthesia Phase 3
43 Chlorpheniramine, phenylpropanolamine drug combination Phase 3,Not Applicable
44 Serotonin Agents Phase 3
45 Serotonin Antagonists Phase 3
46 Narcotics Phase 3,Not Applicable
47 Neurotransmitter Agents Phase 3,Phase 2
48 Hematinics Phase 3,Phase 2
49 Heparin, Low-Molecular-Weight Phase 3
50 Analgesics, Opioid Phase 3,Not Applicable

Interventional clinical trials:

(show top 50) (show all 98)
# Name Status NCT ID Phase Drugs
1 Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat Not yet recruiting NCT02920190 Phase 4 Liraglutide
2 RIMAG Study: Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy Completed NCT00259974 Phase 3 Rituximab
3 Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device Completed NCT01210716 Phase 3
4 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
5 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
6 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
7 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
8 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
9 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
10 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
11 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
12 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
13 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
14 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
15 The Treatment of Lenalidomide in Patients With POEMS Syndrome Unknown status NCT00971685 Phase 2 Lenalidomide and dexamethasone
16 Beta Alethine in Treating Patients With Myeloma Unknown status NCT00006466 Phase 1, Phase 2 beta alethine
17 The Efficacy and Safety of ITF2357 in AIS Unknown status NCT00442182 Phase 2 ITF2357
18 Imaging in MGUS, SMM and MM Completed NCT01237054 Phase 2 18-NaF PET;18-FDG PET/CT
19 Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma Completed NCT00099047 Phase 2 celecoxib;placebo
20 Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma Completed NCT00006219 Phase 2 clarithromycin;prasterone
21 Ilaris (Canakinumab) in the Schnitzler Syndrome Completed NCT01245127 Phase 2 Ilaris
22 Investigation of the Enhancement of Response to Hepatitis B Vaccine by Lenalidomide in Plasma Cell Dyscrasias Completed NCT02041325 Phase 2 Lenalidomide;Placebo
23 Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00001287 Phase 2 intravenous immunoglobulin (IVIg)
24 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00005804 Phase 2 cyclophosphamide
25 Non-Ablative Allo HSCT For Hematologic Malignancies or SAA Completed NCT00006379 Phase 2 cyclophosphamide;fludarabine phosphate
26 Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer Completed NCT00002504 Phase 2
27 Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer Completed NCT00003406 Phase 1, Phase 2 carboplatin;docetaxel;ifosfamide
28 Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy Completed NCT00416624 Phase 2 darbepoetin alfa;epoetin alfa
29 Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer Completed NCT00255749 Phase 2
30 Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00245037 Phase 1, Phase 2 busulfan;cyclosporine;fludarabine phosphate;mycophenolate mofetil;Granulocyte colony-stimulating factor (G-CSF);Phenytoin;Methotrexate
31 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis Completed NCT00132015 Phase 2 tanespimycin
32 Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant Completed NCT00110045 Phase 2 caspofungin acetate
33 A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma Completed NCT01063907 Phase 1, Phase 2 KW-2478;Bortezomib
34 Efficacy and Safety of Canakinumab in Schnitzler Syndrome Completed NCT01276522 Phase 2 Canakinumab
35 Safety and Tolerability of Rilonacept in Muckle-Wells Syndrome (MWS) or Schnitzler Syndrome (SchS) Completed NCT01045772 Phase 2 rilonacept
36 Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma Recruiting NCT03236428 Phase 2 Daratumumab
37 Daratumumab in Treatment of PGNMID and C3 GN Recruiting NCT03095118 Phase 2 Daratumumab
38 Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome Recruiting NCT02921893 Phase 2 Dexamethasone;Ixazomib Citrate;Lenalidomide
39 Tocilizumab in Patients With Schnitzler's Syndrome Recruiting NCT03046381 Phase 2 Tocilizumab
40 Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients Active, not recruiting NCT02566265 Phase 2
41 Ilaris® Effects in Schnitzler Syndrome (ILESCH) Active, not recruiting NCT01390350 Phase 2 Canakinumab;Placebo
42 Study of Lenalidomide as a Treatment for Neuropathy Associated With Monoclonal Gammopathy of Undetermined Significance Terminated NCT00665652 Phase 2 Lenalidomide
43 Rituximab in Treating Patients With Peripheral Neuropathy Caused by Monoclonal Gammopathy of Undetermined Significance Terminated NCT00588822 Phase 2
44 Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma Terminated NCT00942422 Phase 2
45 Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM) Terminated NCT00899353 Phase 2
46 Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple Myeloma Terminated NCT00538824 Phase 2 dexamethasone;thalidomide;lenalidomide
47 Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment Terminated NCT01548573 Phase 2 Dexamethasone;Cisplatin;Doxorubicin;Cyclophosphamide;Etoposide;Bortezomib;Thalidomide;Melphalan
48 Imaging Studies and the Development of Multiple Myeloma Withdrawn NCT01571726 Phase 2 Fluciclatide
49 Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer Unknown status NCT00004036 Phase 1 amifostine trihydrate;carboplatin;cyclophosphamide
50 A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma Completed NCT01219010 Phase 1

Search NIH Clinical Center for Monoclonal Gammopathy of Uncertain Significance

Genetic Tests for Monoclonal Gammopathy of Uncertain Significance

Anatomical Context for Monoclonal Gammopathy of Uncertain Significance

MalaCards organs/tissues related to Monoclonal Gammopathy of Uncertain Significance:

41
Bone, Bone Marrow, B Cells, Testes, Liver, Prostate, Heart

Publications for Monoclonal Gammopathy of Uncertain Significance

Articles related to Monoclonal Gammopathy of Uncertain Significance:

(show top 50) (show all 171)
# Title Authors Year
1
Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR). ( 29424556 )
2018
2
Sporadic late-onset nemaline myopathy with monoclonal gammopathy of undetermined significance (SLONM-MGUS): An alternative treatment using cyclophosphamide-thalidomide-dexamethasone (CTD) regimen. ( 29910095 )
2018
3
Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. ( 28479151 )
2018
4
Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma. ( 28540748 )
2018
5
Treatment with bortezomib in dense deposit disease associated with monoclonal gammopathy of undetermined significance. ( 29363742 )
2018
6
The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma. ( 28550183 )
2017
7
Pattern of somatic mutations in patients with WaldenstrAPm macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. ( 28983055 )
2017
8
Management of Patients With Hepatitis C Virus, Monoclonal Gammopathy of Undetermined Significance, and Multiple Myeloma. ( 28748190 )
2017
9
Recurrent alterations of the WW domain containing oxidoreductase gene spanning the common fragile site FRA16D in multiple myeloma and monoclonal gammopathy of undetermined significance. ( 28943951 )
2017
10
Paraproteinemic keratopathy in monoclonal gammopathy of undetermined significance treated with primary keratoprosthesis: Case report, histopathologic findings, and world literature review. ( 29390260 )
2017
11
Diffuse Peritoneal and Bowel Wall Infiltration by Light Chain-AL Amyloidosis with Omental Calcification Mimicking Abdominal Carcinomatosis - An Elderly Female with Incidental Finding of Light Chain Monoclonal Gammopathy of Undetermined Significance (LC-MGUS). ( 29176541 )
2017
12
Bilateral striopallidodentate calcinosis associated with SjAPgren's syndrome and IgDI> monoclonal gammopathy of undetermined significance. ( 29183861 )
2017
13
Sporadic late-onset nemaline myopathy with monoclonal gammopathy of undetermined significance. ( 28678037 )
2017
14
Pure Red Cell Aplasia Associated with Monoclonal Gammopathy of Undetermined Significance and Literature Review. ( 28182355 )
2017
15
Prevalence and prognosis implication of MYD88 L265P mutation in IgM monoclonal gammopathy of undetermined significance and smouldering WaldenstrAPm macroglobulinaemia. ( 27605200 )
2017
16
Network-based analysis of the molecular mechanisms of multiple myeloma and monoclonal gammopathy of undetermined significance. ( 28943924 )
2017
17
CD229 Expression on Bone Marrow Plasma Cells from Patients with Multiple Myeloma and Monoclonal Gammopathies of Uncertain Significance. ( 26303094 )
2016
18
Monoclonal gammopathy of undetermined significance and WaldenstrAPm's macroglobulinemia. ( 27825465 )
2016
19
Secondary malignancies in patients with multiple myeloma, WaldenstrAPm macroglobulinemia and monoclonal gammopathy of undetermined significance. ( 27546465 )
2016
20
Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution. ( 27013181 )
2016
21
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM): a practical guide to management. ( 27804161 )
2016
22
A case of severe chronic inflammatory demyelinating polyradiculoneuropathy with monoclonal gammopathy of undetermined significance with alternating immunoglobulin class to IgM from IgA. ( 27580763 )
2016
23
Light chain Fanconi syndrome in a patient with acute myeloid leukemia and monoclonal gammopathy of undetermined significance. ( 28508985 )
2016
24
The Immunotyping Distribution of Serum Monoclonal Paraprotein and Environmental Impact on Multiple Myeloma (MM) and Monoclonal Gammopathy of Uncertain Significance (MGUS) in Taiwan: A Medical Center-Based Experience. ( 26838245 )
2016
25
Nodular mucinosis associated with light-chain monoclonal gammopathy of uncertain significance. ( 27979308 )
2016
26
Hypercalcemia associated with isolated bone marrow sarcoidosis in a patient with underlying monoclonal gammopathy of undetermined significance: case report and review of literature. ( 27651903 )
2016
27
The Hematologic Definition of Monoclonal Gammopathy of Undetermined Significance in Relation to Paraproteinemic Keratopathy (An American Ophthalmological Society Thesis). ( 28050052 )
2016
28
The expression of osteopontin and vascular endothelial growth factor in correlation with angiogenesis in monoclonal gammopathy of undetermined significance and multiple myeloma. ( 26997492 )
2016
29
Quantitative superresolution microscopy reveals differences in nuclear DNA organization of multiple myeloma and monoclonal gammopathy of undetermined significance. ( 25501803 )
2015
30
Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: a population-based retrospective cohort study. ( 26034780 )
2015
31
A case of subcorneal pustular dermatosis with IgG monoclonal gammopathy of undetermined significance: a rare association. ( 26341517 )
2015
32
Transcriptional dysregulation of the deleted in colorectal carcinoma gene in multiple myeloma and monoclonal gammopathy of undetermined significance. ( 26390996 )
2015
33
Analysis of thymidine kinase serum levels by novel method DiviTum in multiple myeloma and monoclonal gammopathy of undetermined significance - comparison with imaging methods 99mTc-MIBI scintigraphy and 18F-FDG PET/CT. ( 24572488 )
2015
34
Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma. ( 24149943 )
2014
35
Comparison of monoclonal gammopathy of undetermined significance-associated neuropathy and chronic inflammatory demyelinating polyneuropathy patients. ( 24801490 )
2014
36
MYC protein expression is detected in plasma cell myeloma but not in monoclonal gammopathy of undetermined significance (MGUS). ( 24705315 )
2014
37
Detection of MYD88 L265P in peripheral blood of patients with WaldenstrAPm's Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. ( 24509637 )
2014
38
Circulating clonotypic B cells in multiple myeloma and monoclonal gammopathy of undetermined significance. ( 23872308 )
2014
39
Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies. ( 24319222 )
2013
40
Clues to pathogenesis of WaldenstrAPm macroglobulinemia and immunoglobulin M monoclonal gammopathy of undetermined significance provided by analysis of immunoglobulin heavy chain gene rearrangement and clustering of B-cell receptors. ( 23442064 )
2013
41
Simultaneous diagnosis of Kaposi's sarcoma, psoriasis, vitiligo and monoclonal gammopathy of undetermined significance in an immunocompetent patient. ( 23594153 )
2013
42
Arterial and venous thrombosis in patients with monoclonal gammopathy of undetermined significance: incidence and risk factors in a cohort of 1491 patients. ( 23240810 )
2013
43
Single-nucleotide polymorphism rs1052501 associated with monoclonal gammopathy of undetermined significance and multiple myeloma. ( 22945773 )
2013
44
Monoclonal gammopathy of undetermined significance and fatal polyarteritis nodosa. ( 23942636 )
2013
45
Microarray demonstrates different gene expression profiling signatures between WaldenstrAPm macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. ( 23477935 )
2013
46
Renal thrombotic microangiopathies/thrombotic thrombocytopenic purpura in a patient with primary SjAPgren's syndrome complicated with IgM monoclonal gammopathy of undetermined significance. ( 20652270 )
2013
47
Immunoglobulin m monoclonal gammopathy of undetermined significance and smoldering WaldenstrAPm macroglobulinemia. ( 23490989 )
2013
48
MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance. ( 24072850 )
2013
49
Concomitant transformation of monoclonal gammopathy of undetermined significance to multiple myeloma and of essential thrombocythemia to acute biphenotypic leukemia 37 years after initial diagnosis. ( 24086946 )
2013
50
Involved/uninvolved immunoglobulin ratio identifies monoclonal gammopathy of undetermined significance patients at high risk of progression to multiple myeloma. ( 24261626 )
2013

Variations for Monoclonal Gammopathy of Uncertain Significance

Copy number variations for Monoclonal Gammopathy of Uncertain Significance from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13350 1 1 125000000 Gain Monoclonal gammopathy of undetermined significance
2 16482 1 125000000 249250621 Gain Monoclonal gammopathy of undetermined significance
3 55476 11 53700000 135006516 Gain Monoclonal gammopathy of undetermined significance
4 76533 13 32200000 40100000 Deletion NBEA Monoclonal gammopathy of undetermined significance
5 82835 14 17600000 107349540 Loss Monoclonal gammopathy of undetermined significance
6 89754 15 19000000 102531392 Gain Monoclonal gammopathy of undetermined significance
7 124088 19 1 26500000 Gain Monoclonal gammopathy of undetermined significance
8 166137 3 1 91000000 Gain Monoclonal gammopathy of undetermined significance
9 214491 6 61000000 171115067 Loss Monoclonal gammopathy of undetermined significance
10 253951 9 49000000 141213431 Gain Monoclonal gammopathy of undetermined significance

Expression for Monoclonal Gammopathy of Uncertain Significance

Search GEO for disease gene expression data for Monoclonal Gammopathy of Uncertain Significance.

Pathways for Monoclonal Gammopathy of Uncertain Significance

Pathways related to Monoclonal Gammopathy of Uncertain Significance according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.11 B2M CD40LG IL6 LTA NCAM1 TNF
2
Show member pathways
12.62 B2M CD40LG IL6 LTA TNF
3
Show member pathways
12.49 CD40LG IL6 LTA TNF
4 12.01 B2M CD19 CD38 CD40LG CD79A NCAM1
5 11.91 CD40LG MAG NCAM1
6 11.85 B2M CD19 CD40LG
7 11.79 IL6 MAG TNF
8 11.72 IL6 LTA TNF
9 11.65 CD40LG LTA TNF
10 11.54 LTA NCAM1 TNF
11 11.54 CD19 CD38 IL6 TNF
12 11.42 CD19 CD38 IL6 NCAM1 TNF
13
Show member pathways
11.41 CD40LG IL6 TNF
14 11.3 CD19 CD38 CD40LG
15 11.23 CD40LG IL6 TNF
16 11.16 CD19 CD38 CD79A IL6 NCAM1 TNF
17 11.07 CD19 CD40LG CD79A
18 10.93 IL6 TNF
19 10.84 IL6 TNF

GO Terms for Monoclonal Gammopathy of Uncertain Significance

Cellular components related to Monoclonal Gammopathy of Uncertain Significance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.35 B2M CD38 CD40LG NCAM1 TNF
2 external side of plasma membrane GO:0009897 9.1 B2M CD19 CD40LG CD79A NCAM1 TNF

Biological processes related to Monoclonal Gammopathy of Uncertain Significance according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.85 CD40LG IL6 LTA TNF
2 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.71 CD40LG IL6 TNF
3 tumor necrosis factor-mediated signaling pathway GO:0033209 9.69 CD40LG LTA TNF
4 immune response GO:0006955 9.65 B2M CD40LG IL6 LTA TNF
5 defense response to Gram-positive bacterium GO:0050830 9.63 IL6 LTA TNF
6 B cell receptor signaling pathway GO:0050853 9.61 CD19 CD38 CD79A
7 negative regulation of neuron projection development GO:0010977 9.54 B2M CD38 MAG
8 positive regulation of chemokine production GO:0032722 9.52 IL6 TNF
9 humoral immune response GO:0006959 9.5 IL6 LTA TNF
10 negative regulation of growth of symbiont in host GO:0044130 9.49 LTA TNF
11 negative regulation of bone resorption GO:0045779 9.48 CD38 IL6
12 negative regulation of lipid storage GO:0010888 9.4 IL6 TNF
13 regulation of immunoglobulin secretion GO:0051023 9.16 CD40LG TNF
14 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 8.96 LTA TNF
15 positive regulation of chronic inflammatory response to antigenic stimulus GO:0002876 8.62 LTA TNF

Molecular functions related to Monoclonal Gammopathy of Uncertain Significance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.26 CD40LG IL6 LTA TNF
2 tumor necrosis factor receptor binding GO:0005164 8.8 CD40LG LTA TNF

Sources for Monoclonal Gammopathy of Uncertain Significance

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....